Oxycodone extended release- Ensysce Biosciences

Drug Profile

Oxycodone extended release- Ensysce Biosciences

Alternative Names: BIO-MD™ PF614; ER Oxycodone - Ensysce Biosciences; ER Oxycodone Bio-MD™ System; PF 614; PRF 06014; PRF06104

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 04 Dec 2017 Ensysce Biosciences re-initiates a phase I trial in Pain (In volunteers) in USA (PO) (NCT02454712)
  • 03 Apr 2017 Ensysce Biosciences completes a phase I trial in Pain (In volunteers) in USA (PO)
  • 16 Dec 2016 Extended release oxycodone is available for licensing as of 16 Dec 2016. www.signaturerx.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top